Literature DB >> 19183147

Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.

P Rozen1, Z Levi, R Hazazi, A Waked, A Vilkin, E Maoz, S Birkenfeld, M Leshno, Y Niv.   

Abstract

BACKGROUND: Faecal occult blood tests (FOBT) are faulted by low sensitivity for advanced adenomatous polyps (AAP). Quantified, immunochemical, haemoglobin (Hb)-specific immunochemical FOBT (I-FOBT) measurements are now used for colorectal screening. AIMS: To correlate adenoma characteristics to amount of faecal Hb lost and to evaluate sensitivity and specificity for AAP by faecal Hb development threshold used and number of I-FOBTs collected.
METHODS: Three daily I-FOBTs were collected and analysed in 1221 patients scheduled for colonoscopy. Faecal Hb was analysed as ngHb/mL of buffer and the highest result related to colonoscopy findings.
RESULTS: In 1204 patients without cancer, colonoscopy identified adenomas in 294, 99 with AAPs. Adenoma patients had elevated faecal Hb increasing with advanced histology, size, pedunculated shape and multiplicity (P < 0.001 for all). At 50 ngHb/mL threshold, sensitivity and specificity for AAPs were 54.5% (95%CI 44.7, 64.7) and 88.1% (95%CI 86.2, 90.1) for three tests. At higher thresholds, sensitivity decreased, but was significantly higher with more samples collected. Conversely, specificity increased at higher thresholds, but decreased with more samples.
CONCLUSIONS: Faecal Hb loss from adenomas is significantly associated with size, number and advanced features. Sensitivity and specificity for AAPs are determined by test threshold chosen and number of samples collected; these determine the number of colonoscopies needed for positive tests.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19183147     DOI: 10.1111/j.1365-2036.2009.03946.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  13 in total

1.  Similar fecal immunochemical test results in screening and referral colorectal cancer.

Authors:  Sietze T van Turenhout; Leo G M van Rossum; Frank A Oort; Robert J F Laheij; Anne F van Rijn; Jochim S Terhaar sive Droste; Paul Fockens; René W M van der Hulst; Anneke A Bouman; Jan B M J Jansen; Gerrit A Meijer; Evelien Dekker; Chris J J Mulder
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

2.  Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia.

Authors:  U Haug; K M Kuntz; A B Knudsen; S Hundt; H Brenner
Journal:  Br J Cancer       Date:  2011-05-10       Impact factor: 7.640

3.  The value of age and medical history for predicting colorectal cancer and adenomas in people referred for colonoscopy.

Authors:  Barbara-Ann Adelstein; Petra Macaskill; Robin M Turner; Peter H Katelaris; Les Irwig
Journal:  BMC Gastroenterol       Date:  2011-09-08       Impact factor: 3.067

4.  Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study.

Authors:  Frank A Oort; Sietze T van Turenhout; Veerle M H Coupé; René W M van der Hulst; Eric I C Wesdorp; Jochim S Terhaar sive Droste; Ilhame Ben Larbi; Shannon L Kanis; Edwin van Hengel; Anneke A Bouman; Gerrit A Meijer; Chris J J Mulder
Journal:  BMC Cancer       Date:  2011-10-10       Impact factor: 4.430

5.  Comparative effectiveness of five fecal immunochemical tests using colonoscopy as the gold standard: study protocol.

Authors:  Barcey T Levy; Jeanette M Daly; Yinghui Xu; Seth D Crockett; Richard M Hoffman; Jeffrey D Dawson; Kim Parang; Navkiran K Shokar; Daniel S Reuland; Marc J Zuckerman; Avraham Levin
Journal:  Contemp Clin Trials       Date:  2021-05-08       Impact factor: 2.261

6.  Prospective cross-sectional study on faecal immunochemical tests: sex specific cut-off values to obtain equal sensitivity for colorectal cancer?

Authors:  Sietze T van Turenhout; Frank A Oort; René W M van der Hulst; Arjen P Visscher; Jochim S Terhaar sive Droste; Pieter Scholten; Anneke A Bouman; Gerrit A Meijer; Chris J J Mulder; Leo G M van Rossum; Veerle M H Coupé
Journal:  BMC Gastroenterol       Date:  2014-12-21       Impact factor: 3.067

Review 7.  Which Fecal Immunochemical Test Should I Choose?

Authors:  Jeanette M Daly; Yinghui Xu; Barcey T Levy
Journal:  J Prim Care Community Health       Date:  2017-04-27

Review 8.  Developments in Screening Tests and Strategies for Colorectal Cancer.

Authors:  Justin L Sovich; Zachary Sartor; Subhasis Misra
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

9.  The performance of three-sample qualitative immunochemical fecal test to detect colorectal adenoma and cancer in gastrointestinal outpatients: an observational study.

Authors:  Dong Wu; Han-Qing Luo; Wei-Xun Zhou; Jia-Ming Qian; Jing-Nan Li
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

10.  Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study.

Authors:  Elizabeth G Liles; Nancy Perrin; Ana G Rosales; David H Smith; Adrianne C Feldstein; David M Mosen; Theodore R Levin
Journal:  BMC Cancer       Date:  2018-05-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.